> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Elemental Impurities Guidance
- URL: https://www.fdaweb.com/elemental-impurities-guidance/
- Published: 2022-09-15T12:00:00.000Z
- Updated: 2026-09-14T17:59:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152748

FDA has published an International Conference for Harmonization guidance, *Q3D(R2) Elemental Impurities*, on controlling within acceptable limits elemental impurities in drug products. The [document](https://www.fda.gov/media/148474/download?ref=fdaweb.com) contains three parts:

- the evaluation of the toxicity data for potential elemental impurities;
- the establishment of a permitted daily exposure (PDE) for each element of toxicological concern; and
- the application of a risk-based approach to control elemental impurities in drug products.

“An applicant is not expected to tighten the limits based on process capability, provided that the elemental impurities in drug products do not exceed the PDEs,” the guidance says. “The PDEs established in this guidance are considered to be protective of public health for all patient populations. In some cases, lower levels of elemental impurities may be warranted when levels below toxicity thresholds have been shown to have an impact on other quality attributes of the drug product.”